- Home
- SPFI vs CGEM Comparison
SPFI vs CGEM Comparison
Compare SPFI & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | CGEM |
|---|---|---|
| Founded | 1941 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.4M | 671.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPFI | CGEM |
|---|---|---|
| Price | $40.58 | $10.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $42.25 | $28.13 |
| AVG Volume (30 Days) | 64.7K | ★ 905.4K |
| Earning Date | 01-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 36.91 | N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $205,251,000.00 | N/A |
| Revenue This Year | $13.88 | N/A |
| Revenue Next Year | $13.05 | N/A |
| P/E Ratio | $11.47 | ★ N/A |
| Revenue Growth | ★ 11.60 | N/A |
| 52 Week Low | $30.01 | $5.68 |
| 52 Week High | $42.38 | $13.33 |
Technical Indicators
Market Signals| Indicator | SPFI | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 54.12 |
| Support Level | $38.91 | $10.04 |
| Resistance Level | $40.15 | $11.24 |
| Average True Range (ATR) | 0.95 | 0.66 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 97.28 | 63.93 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.